NCT05681871

Brief Summary

Preoperative anaemia has been shown to be associated with worse outcomes after surgery in both adults and children. Limited research has been done on how common preoperative iron-deficiency anaemia (IDA) is in children and how best to treat it. Oral iron is a relatively cost-effective treatment for IDA. This study aims to show whether giving children with IDA oral iron for 6-12 weeks before their surgery significantly improves their haemoglobin.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
755

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Feb 2023

Typical duration for phase_4

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 3, 2023

Completed
9 days until next milestone

First Posted

Study publicly available on registry

January 12, 2023

Completed
28 days until next milestone

Study Start

First participant enrolled

February 9, 2023

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 31, 2025

Completed
Last Updated

September 18, 2025

Status Verified

September 1, 2025

Enrollment Period

2.3 years

First QC Date

January 3, 2023

Last Update Submit

September 12, 2025

Conditions

Keywords

SAPSOS2

Outcome Measures

Primary Outcomes (1)

  • Delta Haemoglobin = Change in haemoglobin pre- and post- oral iron supplementation

    g/dL

    4-12 weeks

Secondary Outcomes (1)

  • Incidence of iron-deficiency anaemia

    24 months

Study Arms (1)

Iron-deficiency anaemia

EXPERIMENTAL

Participants will receive oral iron supplementation for a minimum of 4 weeks prior to surgery

Dietary Supplement: Ferrous gluconate syrup or ferrous fumarate/folic acid tablets

Interventions

Oral iron supplementation dosed based on body weight

Iron-deficiency anaemia

Eligibility Criteria

Age6 Months - 16 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Age \> 6 months to \<16 years
  • Noncardiac surgery
  • Elective surgery
  • Anaemic as per World Health Organisation criteria

You may not qualify if:

  • Patient or parent refusal
  • Unable to obtain written consent at the surgical outpatient clinic
  • Surgery planned within 4 weeks from surgical outpatient visit
  • Known history of acquired iron overload, family history of haemochromatosis or thalassemia
  • Known reason for anaemia (e.g., untreated vitamin B12 or folate deficiency or haemoglobinopathy)
  • Treatment with oral iron, erythropoietin, IV iron therapy or blood transfusion in the previous 12 weeks
  • Known hypersensitivity to oral iron or other contraindication to oral iron
  • Temperature \> 38.0 °C or receiving non-prophylactic antibiotics
  • Acute liver failure

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Tygerberg Hospital

Cape Town, Western Cape, 7505, South Africa

Location

Red Cross War Memorial Children's Hospital

Cape Town, Western Cape, 7700, South Africa

Location

MeSH Terms

Conditions

AnemiaAnemia, Iron-Deficiency

Interventions

ferrous fumarateFolic Acid

Condition Hierarchy (Ancestors)

Hematologic DiseasesHemic and Lymphatic DiseasesAnemia, HypochromicIron DeficienciesIron Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

PterinsPteridinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Study Officials

  • Heidi M Meyer, MBChB

    University of CapeTown

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: Prospective interventional quasi-experimental pre-post study South African multi-centre
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator, Specialist Anaesthetist, Division of Paediatric Anaesthesia, Department of Anaesthesia & Perioperative Medicine

Study Record Dates

First Submitted

January 3, 2023

First Posted

January 12, 2023

Study Start

February 9, 2023

Primary Completion

May 31, 2025

Study Completion

May 31, 2025

Last Updated

September 18, 2025

Record last verified: 2025-09

Data Sharing

IPD Sharing
Will share

Data sharing agreement has been finalised between the University of Cape Town and Professor Susan Goobie and Dr. Steven Staffa at Boston Children's Hospital. Purpose of this agreement is for statistical analysis and manuscript development. All shared data will undergo de-identification. Shared data includes eligibility, consent, reasons for exclusion, and de-identified record IDs, patient demographics, comorbidities, deworming status, planned date of surgery, hemocue results, pre-intervention formal Hb, MCV, reticulocyte count, CRP, ferritin levels, TSAT, information regarding medication compliance and any experienced side-effects, date of repeat Hb and post-intervention formal Hb, and serious adverse events.

Shared Documents
STUDY PROTOCOL, SAP
Time Frame
Data requests can be submitted starting 9 months after article publication and the data will be made accessible for up to 24 months. Extensions will be considered on a case-by-case basis.
Access Criteria
Access to trial IPD can be requested by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information or to submit a request, please contact researchcontracts@uct.ac.za

Locations